SRRK - Scholar Rock Holding Corp logo

Scholar Rock Holding Corp

SRRK

Scholar Rock Holding Corporation develops biopharmaceuticals targeting neuromuscular diseases like spinal muscular atrophy. Its pipeline includes monoclonal antibodies aimed at activating growth factors, with therapies in various clinical trial stages.

⚕️ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago →$1,584today

Score Overview

1 Year
Score—
Net Growth-8.11%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score1.4
Net Growth-210.01%
Net Trend20%
Net Income Consistency—
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency—
All Time
Score—
Net Growth-6x
Net Trend13%
Net Income Consistency
Rev Growth—
Rev Trend38%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Scholar Rock Holding Corp has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. SRRK does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 41.49—
1 Year2025-10-23
$ 28.6644.77%
5 Years2021-10-22
$ 26.1958.42%
All Time2018-05-24
$ 15.50167.68%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 408M$ 492M
2025$ 0.00-$ 377M$ 367M
2024$ 0.00-$ 246M$ 437M
2023$ 0.00-$ 165M$ 279M
2022$ 33M-$ 131M$ 315M
2021$ 18M-$ 131M$ 252M
2020$ 15M-$ 84M$ 341M
2019$ 20M-$ 49M$ 157M
IPO2018$ 0.00-$ 49M$ 175M
SRRK - Scholar Rock Holding Corp logo

Scholar Rock Holding Corp fundamental performance

Between 2020 and 2025, revenue declined from $ 15M to $ 0.00 and net income went from -$ 84M to -$ 377M. Revenue increased in 1 of those 5 years; net income in 1.

Scholar Rock Holding Corp currently holds a 5-year HDB Score of 1.4 out of 10. How the HDB Score is calculated.

Membership

Explore SRRK with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies